Skip to main content
Clinical Trials/NL-OMON34258
NL-OMON34258
Not yet recruiting
Not Applicable

Validation of cholesterol absorption as measured by the dual isotope method - DAHLIA-2B

Academisch Medisch Centrum0 sites7 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
mild hypercholesterolemia
Sponsor
Academisch Medisch Centrum
Enrollment
7
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Healthy male and female subjects, aged 18\-65 years, with an LDL\-cholesterol concentration between 3\.0 and 5\.0 mmol/l, who participated in the Dahlia\-2a study and who do not use any cholesterol\-lowering medication.

Exclusion Criteria

  • Excluded are persons with a genetic hyperlipoproteinemia like familial hypercholesterolemia, LPL\-deficiency, familial dysbeta lipoproteinemia and familial hypertriglyceridemia. Also people with diabetes mellitus, severe hypertriglyceridemia, uncontrolled hypertension or history of arterial disease including unstable angina, myocardial infarction, recent transient ischaemic attacks or a cerebro\-vascular accidents, will be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSoundpatients aged 30-85 years who were undergoing percutaneous coronary intervention (PCI, elective or emergency) with &gt=1 significant stenosis &gt=75% and &gt=1 untouched nonculprit lesion of &lt=50% stenosis that could be imaged by intravascular ultrasound, and either LDL-C &gt=100 mg/dl.
JPRN-UMIN000002959Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University300
Completed
Not Applicable
The study about the effects of cholesterol absorption inhibition on coronary artery plaque in patients treated with PCIcoronary artery diseases
JPRN-UMIN000026581Kurume University Medical Center50
Completed
Phase 4
Therapeutic effects of cholesterol absorption inhibitor on renal function in patients with chronic kidney diseaseChronic kidney disease Hypercholesterolemia
JPRN-UMIN000002528Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine50
Recruiting
Not Applicable
Serum levels of Cholesterol synthesis/absorption markers in subjects of various diseases.ormal subjects, Diabetes, Hyperlipidemia, Essential hypertension, Metabolic syndrome
JPRN-UMIN000004946Department of Metabolic Medicine, Faculty of life sciences, Kumamoto University600
Not yet recruiting
Not Applicable
The difference in fractional cholesterol absorption between subjects with high versus low plasma campesterol levelsmild hypercholesterolaemiaslightly elevated cholesterol10013317
NL-OMON32507Academisch Medisch Centrum13